Sugi Predict

Sugi Predict / Compounds / SCHEMBL607046

SCHEMBL607046

SCHEMBL607046

CCCCCc1ccc(S(N)(=O)=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 18/20 1.00
▸ SMN1; SMN2 Q16637 2/20 0.89
▸ CA1 P00915 11/20 0.70
▸ CA9 Q16790 11/20 0.70
▸ CA12 O43570 6/20 0.70
▸ CA7 P43166 5/20 0.60
▸ CA5A P35218 3/20 0.60
▸ CA5B Q9Y2D0 3/20 0.60
▸ CA4 P22748 2/20 0.60
▸ CA6 P23280 2/20 0.60
▸ CA14 Q9ULX7 2/20 0.60
▸ HSD17B10 Q99714 1/20 0.59
▸ TSHR P16473 1/20 0.58
▸ MEN1 O00255 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ KMT2A Q03164 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10661919 0.98 CA2 (0.96) CA2SMN1; SMN2CA1CA9CA12
SCHEMBL9126817 0.98 CA2 (0.96) CA2SMN1; SMN2CA1CA9CA12
SCHEMBL7898294 0.98 CA2 (0.96) CA2SMN1; SMN2CA1CA9CA12
SCHEMBL28640316 0.98 CA2 (0.96) CA2SMN1; SMN2CA1CA9CA12
SCHEMBL17817182 0.98 CA2 (0.96) CA2SMN1; SMN2CA1CA9CA12
SCHEMBL78265 0.98 CA2 (0.96) CA2SMN1; SMN2CA1CA9CA12
SCHEMBL607623 0.94 CA2 (1.00) CA2SMN1; SMN2CA1CA9CA12
Acetic Acid SCHEMBL28872225 0.92 CA2 (0.84) CA2SMN1; SMN2CA1CA9CA12
SCHEMBL18122304 0.89 CA2 (0.89) CA2SMN1; SMN2CA1CA9CA12
SCHEMBL429778 0.86 CA2 (1.00) CA2SMN1; SMN2CA1CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 — — US claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 — — US claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 — — EP claimed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 — — US claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 — — EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 — — US claimed
EP-4452956-A1 BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2024-10-30 — — EP disclosed
CN-118574812-A Benzenesulfonamide thiazole compounds and their use for the treatment of cancer 国家医疗保健研究所 2024-08-30 — — CN disclosed
WO-2023118373-A1 BENZENE SULFONAMIDE THIAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCERS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2023-06-29 — — WO disclosed
US-11254686-B1 Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor CORVUS PHARMACEUTICALS, INC. (US) 2022-02-22 — — US disclosed
EP-2827883-B1 TFPI INHIBITORS AND METHODS OF USE Baxalta GmbH (CH) 2019-05-08 — — EP disclosed
CN-108431144-A aqueous ink and ink jet printing method 柯尼卡美能达株式会社 2018-08-21 — — CN disclosed
EP-1660507-B2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME MILLENNIUM PHARM INC (US) 2017-01-04 — — EP disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 — — US disclosed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 — — EP disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 — — US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 — — US disclosed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 — — EP disclosed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 — — US disclosed
US-4044151-A Sulfamidophenethanolamine therapeutic process MEAD JOHNSON & COMPANY (US) 1977-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 CA2 2765/4885SMN1; SMN2 1107/4885CA1 902/4885
US-11254686-B1 Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor ADORA2A, ADORA2B, ADORA3 CA2 1563/4885SMN1; SMN2 4581/4885CA1 2878/4885
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 CA2 2765/4885SMN1; SMN2 1107/4885CA1 902/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 CA2 2765/4885SMN1; SMN2 1107/4885CA1 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.